Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency.
To clarify the mechanism of cardiac hypertrophy in carnitine-deficient JVS mice, we studied the possible role of catecholamine metabolism. Cardiac hypertrophy occurs 2 weeks after birth. The turnover of norepinephrine in the ventricles of JVS mice at 2 weeks was 3 times that of control, but it was not different from control at 5 days when the heart weight was not changed. To evaluate the accelerated norepinephrine turnover, we examined the effects of catecholamine metabolism inhibitors (alpha-methyltyrosine and 6-hydroxydopamine) and catecholamine receptor blockades (propranolol, prazosin and yohimbine) on the ratio of heart weight to body weight (HW/BW) and on the augmented expression of atrial natriuretic peptide (ANP) and the down-regulated carnitine deficiency-associated gene expressed in ventricle (CDV-1). The HW/BW ratio in JVS mice treated with catecholamine metabolism inhibitors and receptor blockades was significantly lower than in JVS mice without treatment, but still higher than in controls treated with each drug and in JVS mice treated with carnitine. The HW/BW ratio of JVS mice with propranolol was not significantly different from that of JVS mice treated with catecholamine metabolism inhibitors and was significantly lower than that of JVS mice treated with prazosin and yohimbine. Northern blot analysis showed that the altered expression of ANP and CDV-1 was not corrected in the ventricles of JVS mice treated with any of the drugs except carnitine. These results suggest that the catecholamine metabolism accelerated in JVS mice ventricles at 2 weeks is not the major cause of cardiac hypertrophy, but probably promotes cardiac hypertrophy mainly through the beta-adrenergic signaling pathway. The aberrant gene expression of ANP and CDV-1 found in JVS mice seems to be independent of catecholamine metabolism, and mediated primarily by the systemic carnitine deficiency.
Jalil
A
A
Department of Biochemistry, Faculty of Medicine, Kagoshima University, Japan.
Horiuchi
M
M
Nomoto
M
M
Kobayashi
K
K
Saheki
T
T
D018674:Adrenergic Antagonists / Q000494:pharmacology*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000235:genetics; D001835:Body Weight / Q000187:drug effects; D006332:Cardiomegaly / Q000209:etiology* / Q000517:prevention & control; D002331:Carnitine / Q000172:deficiency*; D016572:Cyclosporine / Q000494:pharmacology; D004195:Disease Models, Animal; D051379:Mice; D008869:Microtubule-Associated Proteins; D009124:Muscle Proteins / Q000235:genetics; D009638:Norepinephrine / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis
D018674:Adrenergic Antagonists; C106619:Ift81 protein, mouse; D008869:Microtubule-Associated Proteins; D009124:Muscle Proteins; D012333:RNA, Messenger; D016572:Cyclosporine; D009320:Atrial Natriuretic Factor; D002331:Carnitine; D009638:Norepinephrine